ABSTRACT
Finasteride is widely used for the treatment of benign prostatic hyperplasia [BPH]. Its therapeutic efficacy is believed to be mediated through selective inhibition of prostatic 5 alpha- reductase [type II]. The recommended dosage is 5 mg a day. However some studies have show effectiveness with lower doses. The aim of this study is to determine whether patients under 5mg Finasteride can maintain improvements in urinary obstruction when treated with 2.5 mg of finasteride daily for one year. 54 patients with benign prostatic hyperplasia, previously treated for at least one year with 5mg of finasteride, took 2.5 mg of finasteride daily for one year, Assessment included AUA flow rate, voided volume, or AUA symptom score after one year of finasteride 2.5 mg daily therapy. So, we can conclude that the daily dose of finasteride can be reduced to 2.5 mg daily without significant effect on subjective and objective measures of urinary obstruction in patients with BPH